Longrunn Medical Technologies was established in Singapore. Our team has more than 20 years of research experience and aims to develop natural, safe and effective products targeted at improving cellular health and reversing insulin resistance.
MISSION
At LONGRUNN MEDICAL TECHNOLOGIES - LRMT, we are dedicated to revolutionizing health through cellular nutrition. Our mission is to create a comprehensive ecosystem of supplement and health food that empowers individuals to achieve optimal wellness. Through continuous research and development of targeted supplements, we address conditions related to insulin resistance, diabetes, and liver deficiencies. Committed to holistic health and innovative nutritional solutions, we strive to enhance lives by tackling the root causes of metabolic and endrocrine imbalances. We believe in the power of nutrition to transform health at the cellular level, fostering a future where everyone can thrive.
VISION
Our vision is to be a global leader in cellular nutrition, pioneering transformative health solutions that empower individuals to overcome diabetes, insulin resistance, liver deficiencies, and endocrine disorders, as well as other health conditions resulting from these. We aim to build a supportive, inclusive ecosystem where cutting-edge science meets compassionate care, ultimately creating a world where optimal health is accessible to all. Through relentless research and innovation, we aspire to develop supplements that specifically target and alleviate these conditions, contributing to a healthier, more vibrant world.
CORE COMPETITIVE ADVANTAGE
LONGRUNN MEDICAL TECHNOLOGIES owns a patented ingredient, EFILA which is derived from a unique microbial strain extracted from Korean Pine Tree Mushrooms. This microbial strain then undergoes a precise fermentation process using a technology was awarded an Invention Patent for the manufacturing method of Ceriporia Lacerata culture broth extracts and pharmaceutical composition for prevention and treatment of Diabetic Disease and diabetic complications.
Another competitive advantage we have is our fully integrated system, encompassing scientific research, raw material manufacturing, product manufacturing, to final packaging. This ensures quality measures are met at every stage.
LONGRUNN MEDICAL TECHNOLOGIES has a special interest in the study of diabetes. James Li, the President of Longrunn Group, was a diabetic patient himself when he was introduced to the then, DM Supplement, now re-branded EFILA Blood Sugar Control. After consuming DM for 3 weeks, his fasting glucose result dropped from the 20s, to 6-7. Amazed by the efficacy of the supplement, he decided to share this breakthrough with the world.
WHAT IS DIABETES?
Many patients are unaware that high blood sugar is merely a symptom of diabetes, not the disease itself. Diabetes arises when the body either does not produce enough insulin to metabolize the sugar we consume or when the body becomes resistant to insulin, preventing sugar from being absorbed by cells and converted into energy.
While commonly prescribed medications may alleviate symptoms, they often do not address the underlying condition. At LONGRUNN MEDICAL TECHNOLOGIES, we are committed to changing this. Backed by extensive efficacy tests, our goal is to make our products accessible to the global diabetic community and enhance their quality of life through the development of health food products tailored to their needs.
PATENTS
LONGRUNN MEDICAL TECHNOLOGIES was awarded multiple patents in over the last 20 years, including INVENTION PATENT in Korea and China. Application for patent in America and PCT Patent is in progress. In total, 8 PATENTS have been registered in South Korea.
•"Method for producing an extract of Ceriporia lacerata culture fluid for prevention and treatment of diabetes and the extract of Ceriporia lacerata culture fluid"
•"Pharmaceutical product for improvement of sexual function containing extracellular polysaccharides produced by Ceriporia lacerata as an effective ingredient"
•"Product for lowering blood pressure containing extracellular polysaccharides produced by Ceriporia lacerata as an effective ingredient"
•"Stable nerve product containing extracellular polysaccharides produced by Ceriporia lacerata as an effective ingredient"
•"Product for prevention and treatment of skin inflammation containing culture fluid of Ceriporia lamaritus strain as an effective ingredient"
•"Product for prevention and treatment of diabetes containing Ceriporia lacerata-K1 strain and its culture fluid as effective ingredients"
•"Product for prevention and treatment of liver damage using bilayer culture of Ganoderma lucidum and Ceriporialacerata-K1 mycelium as effective ingredients"
•"Product for prevention and treatment of diabetes using bilayer culture of Ganoderma lucidum and Ceriporia lacerata-K1 mycelium as effective ingredients"
Our patented microbial has also been deposited in the Micro-organism National Depository from June 1 2021.
TOXICITY AND SAFETY TESTS
Since the beginning of the research, there has been multiple clinical tests done including:
- 5 general toxicity tests
- 3 genetic toxicity tests
- 2 efficacy tests
- 3 safety pharmacology tests.
|
Type of
experiment
|
No.
|
Name of experiment
|
Results
|
|
General
toxicity study
(5 items)
|
1
|
Utilize Beagle dogs for repeated oral administration of DRF experiment for 4 weeks.
|
Non-toxic
|
|
2
|
Utilize Beagle dogs for repeated oral administration in a 13-week toxicity study and a 4-week recovery study.
|
Non-toxic
|
|
3
|
Utilize Sprague-Dawley rats for a single oral dose toxicity study.
|
Non-toxic
|
|
4
|
Utilize Sprague-Dawley rats for a 4-week repeated oral dose toxicity study of DRF.
|
Non-toxic
|
|
5
|
Utilize Sprague-Dawley rats for a 13-week repeated oral dose toxicity study and a 4-week recovery study.
|
Non-toxic
|
|
Genetic
toxicity study (3 items)
|
6
|
Utilize bacterial revertant mutation assays (Salmonella typhimurium, Escherichia coli).
|
Negative
|
|
7
|
Utilize CHL cell chromosomal aberration assay.
|
Negative
|
|
8
|
Utilize male ICR mouse bone marrow micronucleus assay by oral administration
|
Negative
|
|
Efficacy experiments
(2 items)
|
9
|
Utilize ICR mice for a single oral glucose tolerance test (OGTT) efficacy experiment.
|
Observed meaningful
reduction in blood sugar
|
|
10
|
3-week oral administration efficacy experiment for blood glucose reduction in db/db mice
|
Observed meaningful
reduction in blood sugar
|
|
Non-rodent
repeated dose
toxicity and
safety
pharmacology
experiments
(3 items)
|
11
|
Single oral dose central nervous system safety pharmacology experiment in ICR mice
|
No effect ion safety
|
|
12
|
Evaluation experiment on the effects involving the cardiovascular system using a remote testing device after single oral administration in male Beagle dogs (conducted at the Safety Evaluation Research Institute, Korea Research Institute of Chemical Technology).
|
No effect ion safety
|
|
13
|
Evaluation experiment on the impact of hERG Potassium Channel using CHO hERG Cells (conducted at the Safety Evaluation Research Institute, Korea Research Institute of Chemical Technology).
|
No effect ion safety
|
CLINICAL STUDIES
Published five research papers, from in vitro, in vivo to clinical research results, concluded that CL is effective in the treatment of diabetes, and studied its mechanism.
|
1
|
Crude extract of Ceriporia lacerata has a protective effect on dexamethasone-induced cytotoxicity in INS-1 cells via the modulation of PI3K/PKB activity
|
|
2
|
Hypoglycemic effects of submerged culture of Ceriporia lacerata mycelium
|
|
3
|
Effect of submerged culture of Ceriporia lacerata mycelium on GLUT4 protein in db/db mouse
|
|
4
|
Effect of Submerged Culture of Ceriporia lacerata Mycelium on Insulin Signaling Pathway in 3T3-L1 Cell
|
|
5
|
Production of exopolysaccharides by submerged culture of Ceriporia lacerata and their anti-diabetic effect
|
THE MARK OF SAFETY
All the supplements developed and manufactured by Longrunn Medical Technologies are manufactured in a FDA approved facility. Our facilities have also passed stringent checks to ensure that products are manufactured in accordance to best practices.
